Biomea Fusion grants 452,512 stock options to director
Biomea Fusion, Inc. director and officer Rainer M. Erdtmann received a grant of stock options covering 452,512 shares of common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Biomea Fusion, Inc. director and officer Rainer M. Erdtmann received a grant of stock options covering 452,512 shares of common stock. The options have an exercise price of $1.49 per share and expire on March 31, 2036.
According to the terms, the award will vest in 16 substantially equal quarterly installments after April 1, 2026, becoming fully vested and exercisable on April 1, 2030, subject to his continued service with the company. Following this grant, he holds 452,512 derivative securities directly.
Insider Trade Summary
Grant/Award: 452,512 shares
Grant/Award
1 txn
Insider
Erdtmann Rainer M
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 452,512 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 452,512 contracts (Direct)
Footnotes (1)
- F1. The option shall vest and become exercisable in 16 substantially equal quarterly installments after April 1, 2026, such that the award will be fully vested and exercisable on April 1, 2030, subject to the Reporting Person's continued service to the Issuer through each vesting date.
Key Figures
Option grant size: 452,512 options
Exercise price: $1.49 per share
Expiration date: March 31, 2036
+2 more
5 metrics
Option grant size
452,512 options
Stock Option (Right to Buy) granted to Rainer M. Erdtmann
Exercise price
<money>$1.49</money> per share
Exercise price for the granted stock options
Expiration date
<date>March 31, 2036</date>
Option term end date
Vesting completion date
<date>April 1, 2030</date>
Date options become fully vested and exercisable
Post-grant derivative holdings
452,512 derivative securities
Total options held directly after transaction
Key Terms
Stock Option (Right to Buy), exercise price, vesting, Common Stock
4 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
exercise price financial
"conversion_or_exercise_price: "1.4900" per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The option shall vest and become exercisable in 16 substantially equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Common Stock financial
"underlying_security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Biomea Fusion (BMEA) insider Rainer Erdtmann receive in this Form 4?
Rainer M. Erdtmann received a stock option grant for 452,512 shares of Biomea Fusion common stock. The options are a compensation-related award, not an open-market purchase, and give him the right to buy shares at a fixed exercise price.
What is the exercise price and term of the new BMEA stock options?
The granted stock options have an exercise price of $1.49 per share and expire on March 31, 2036. This means Erdtmann can choose to exercise the options at that price any time after they vest and before they expire.
How do the Biomea Fusion (BMEA) options granted to Erdtmann vest?
The options vest in 16 substantially equal quarterly installments after April 1, 2026. They will be fully vested and exercisable on April 1, 2030, provided Erdtmann continues to serve Biomea Fusion through each vesting date.
Is this BMEA Form 4 a stock purchase or a compensation grant?
This Form 4 reflects a compensation grant, coded as an “A” transaction for an award or acquisition. Erdtmann did not buy shares on the open market; he received options to purchase 452,512 shares at a fixed exercise price in the future.
How many Biomea Fusion derivative securities does Erdtmann hold after this grant?
After the grant, Erdtmann holds 452,512 derivative securities directly, all from this stock option award. These represent rights to acquire Biomea Fusion common shares upon future exercise, subject to vesting and the stated expiration date.
Does the BMEA filing mention any special conditions on the option grant?
Yes. The options vest only if Erdtmann continues his service with Biomea Fusion through each vesting date. Full vesting occurs on April 1, 2030, and the options then remain exercisable until their expiration in 2036.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates